Tag Archives: Prolia

August, 2016

  • 29 August

    Amgen Announces Positive Top-Line Results from Late-Stage Prolia Study

    THOUSAND OAKS, Calif., Aug. 29, 2016 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced positive top-line results from the primary analysis conducted in a Phase 3 randomized, double-blind, double-dummy, active-controlled study evaluating the safety and efficacy of Prolia® (denosumab) compared with risedronate in patients receiving glucocorticoid treatment. The study met all …

December, 2015

  • 15 December

    Amgen Reacquires Rights to Three Drugs from GSK

    THOUSAND OAKS, Calif., Dec. 14, 2015 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that it has entered into a definitive agreement with GSK to reacquire all of its remaining rights to Prolia® (denosumab), XGEVA®(denosumab) and Vectibix® (panitumumab) in 48 countries in Asia, South America, Europe, Australia and other regions throughout the world. …